Preferred Label : Narazaciclib;
NCIt synonyms : CDK4/CDK6/ARK5 Inhibitor ON 123300;
NCIt definition : An orally bioavailable inhibitor of NUAK family SNF1-like kinase 1 (AMPK-related protein
kinase 5; ARK5), and the cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), with potential
antineoplastic activity. Upon oral administration,narazaciclib specifically binds
to and inhibits ARK5, which interferes with the activation of ARK5-mediated signal
transduction pathways and reduces cell proliferation in cancer cells that overexpress
ARK5. In addition, ON 123300 inhibits CDK4 and 6 and prevents the phosphorylation
of retinoblastoma (Rb) protein in early G1. Inhibition of Rb phosphorylation prevents
CDK-mediated G1-S phase transition, which causes G1 phase cell cycle arrest, suppresses
DNA synthesis and inhibits cancer cell growth. ARK5, a member of the AMP-activated
protein kinase (AMPK) family, is associated with tumor growth and invasion. Overexpression
of CDK4/6, which is seen in certain types of cancer, causes cell cycle deregulation.;
UNII : QJ8RO3296G;
CAS number : 1357470-29-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1357470-29-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : ON 123300; ON-123300;
NCI Metathesaurus CUI : CL1662152;
Origin ID : C179641;
UMLS CUI : C5706709;
Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
